Outcomes of maraviroc-based regimens in HIV-infected individuals

被引：0
|
作者：
Douthwaite, S. [1 ]
Collier, L. [1 ]
Pennell, A. [1 ]
Uriel, A. [1 ]
Wilkins, E. [1 ]
机构：
[1] N Manchester Grp Hosp, Manchester, Lancs, England
来源：
HIV MEDICINE | 2011年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [1] Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis
    Srinivas, Nithya
    Cottrell, Mackenzie
    Maffuid, Kaitlyn
    Prince, Heather A.
    Nelson, Julie A. E.
    White, Nicole
    Sykes, Craig
    Dellon, Evan S.
    Madanick, Ryan D.
    Shaheen, Nicholas J.
    Gonzalez, Daniel
    Kashuba, Angela D. M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (02)
  • [2] Population pharmacokinetics of boosted saquinavir regimens in HIV-infected individuals
    Dickinson, Laura
    Boffito, Marta
    Back, David
    Khoo, Saye
    Pozniak, Anton
    Byakika-Kibwika, Pauline
    Merry, Concepta
    Autar, Reshma Saskia
    Burger, David
    Aarons, Leon
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (06) : 995 - 996
  • [3] THE ECONOMIC IMPACT OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS IN MEXICO
    Contreras-Hernandez, I
    Rely, K.
    Mould-Quevedo, J.
    Davila-Loaiza, G.
    VALUE IN HEALTH, 2009, 12 (03) : A116 - A116
  • [4] Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
    Acosta, EP
    Wu, HL
    Hammer, SM
    Yu, S
    Kuritzkes, DR
    Walawander, A
    Eron, JJ
    Fichtenbaum, CJ
    Pettinelli, C
    Neath, D
    Ferguson, E
    Saah, AJ
    Gerber, JG
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (03) : 1358 - 1366
  • [5] When and how to use maraviroc in HIV-infected patients
    Soriano, Vincent
    Perno, Carlo-Federico
    Kaiser, Rolf
    Calvez, Vincent
    Gatell, Jose M.
    di Perri, Giovanni
    Pillay, Deenan
    Rockstroh, Juergen
    Geretti, Anna Maria
    AIDS, 2009, 23 (18) : 2377 - 2385
  • [6] A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals
    Chancellor, J., V
    Kuehne, F. C.
    Mollon, P.
    Louie, M.
    Powderly, M. G.
    VALUE IN HEALTH, 2008, 11 (03) : A24 - A25
  • [7] Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico
    Contreras-Hernandez, Iris
    Becker, Debbie
    Chancellor, Jeremy
    Kuehne, Felicitas
    Mould-Quevedo, Joaquin
    Vega, Gabriela
    Marfatia, Shalaka
    VALUE IN HEALTH, 2010, 13 (08) : 903 - 914
  • [8] Maraviroc Concentrations in Seminal Plasma in HIV-Infected Patients
    Manuel Tiraboschi, Juan
    Niubo, Jordi
    Curto, Jordi
    Podzamczer, Daniel
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : E35 - E36
  • [9] Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients
    Manuel Tiraboschi, Juan
    Niubo, Jordi
    Curto, Jordi
    Podzamczer, Daniel
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : 606 - 609
  • [10] A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals
    Kuehne, Felicitas C.
    Chancellor, Jeremy
    Mollon, Patrick
    Myers, Daniela E.
    Louie, Michael
    Powderly, William G.
    HIV CLINICAL TRIALS, 2010, 11 (02): : 80 - 99
12345